Cargando…
Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling
Approximately 20,000 patients per year are diagnosed with esophageal adenocarcinoma (EAC) and malignant pleural mesothelioma (MPM); fewer than 20% survive 5 years. Effective therapeutic strategies are limited although patients receive a combination of chemotherapeutics. These tumors harbor thousands...
Autores principales: | Surman, Deborah R., Xu, Yuan, Lee, Min-Jung, Trepel, Jane, Brown, Kate, Ramineni, Maheshwari, Splawn, Taylor G., Diggs, Laurence P., Hodges, H. Courtney, Davis, Jeremy L., Lee, Hyun-Sung, Burt, Bryan M., Ripley, Robert Taylor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338890/ https://www.ncbi.nlm.nih.gov/pubmed/34088830 http://dx.doi.org/10.1158/1535-7163.MCT-20-0887 |
Ejemplares similares
-
Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy
por: Taylor Ripley, R., et al.
Publicado: (2018) -
Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
por: Lee, Catherine, et al.
Publicado: (2023) -
Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
por: Martinez-Velez, Naiara, et al.
Publicado: (2022) -
Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction
por: Durrant, David E., et al.
Publicado: (2021) -
Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing
por: Inoue, Tomoyoshi, et al.
Publicado: (2021)